Forskolin Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.80 M
- Revenue Growth -16.43%
- Profit Growth 109.64%
- Ebitda -22.51%
- Net Worth 92.82%
- Total Assets -28.06%
About Forskolin Pharma
Forskolin Pharma Private Limited (FPPL) is a Private Limited Indian Non-Government Company incorporated in India on 23 October 2018 (Six years and three months 19 days old ). Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.80 M.
Gangadhar Mallappa, Seshadri Srinivasan, and Madenuru Sreelatha serve as directors at the Company.
Company Details
-
Location
Bangaluru, Karnataka, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51909KA2018PTC117863
-
Company No.
117863
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
23 Oct 2018
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Forskolin Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gangadhar Mallappa
|
Additional Director | 22-Jun-2021 | Current |
|
Seshadri Srinivasan
|
Director | 23-Oct-2018 | Current |
|
Madenuru Sreelatha
|
Director | 23-Oct-2018 | Current |
Financial Performance of Forskolin Pharma.
Forskolin Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 16.43% decrease. The company also saw a substantial improvement in profitability, with a 109.64% increase in profit. The company's net worth Soared by an impressive increase of 92.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Forskolin Pharma?
In 2022, Forskolin Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Audikesh Hospitals Private LimitedGangadhar Mallappa is a mutual person
-
Praghvamsha Pharma Private Limited
Seshadri Srinivasan and Madenuru Sreelatha are mutual person
Charges (Loans)
₹5.80 M
₹0
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 0.58 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Oct 2020 | Axis Bank Limited | ₹5.80 M | Open |
How Many Employees Work at Forskolin Pharma?
Unlock and access historical data on people associated with Forskolin Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Forskolin Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Forskolin Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.